Table 6.
Association between genus-specific HPV seroposivity and BCC, stratified by HPV DNA status of the same HPV type in the tumor
| BCC DNA status |
||||||
|---|---|---|---|---|---|---|
| Positive |
Negative |
|||||
| HPV type | Antibody status | Controls n (%) |
n (%) | OR (95% CI)1 | n (%) | OR (95% CI)1 |
| Genus-β | ||||||
|
| ||||||
| N | 300 | 97 | 98 | |||
|
| ||||||
| Any β | Negative | 121 (40.3) | 26 (26.8) | 1.00 (Reference) | 31 (37.8) | 1.00 (Reference) |
|
| ||||||
| Positive | 179 (59.7) | 71 (73.2) | 1.76 (1.03–3.01) | 61 (62.2) | 1.06 (0.65–1.72) | |
|
| ||||||
| β 1 | ||||||
|
| ||||||
| 5 | Negative | 262 (87.3) | 21 (84) | 1.00 (Reference) | 86 (87.8) | 1.00 (Reference) |
|
| ||||||
| Positive | 38 (12.7) | 4 (16) | 1.17 (0.36–3.87) | 12 (12.2) | 0.91 (0.45–1.86) | |
|
| ||||||
| 8 | Negative | 231 (77) | 14 (53.8) | 1.00 (Reference) | 73 (74.5) | 1.00 (Reference) |
|
| ||||||
| Positive | 69 (23) | 12 (46.2) | 2.77 (1.11–6.94) | 25 (25.5) | 1.02 (0.59–1.77) | |
|
| ||||||
| 20 | Negative | 237 (79) | 0 (0) | 1.00 (Reference) | 74 (75.5) | 1.00 (Reference) |
|
| ||||||
| Positive | 63 (21) | 2 (100) | NA (NA) | 24 (24.5) | 1.13 (0.65–1.96) | |
|
| ||||||
| 24 | Negative | 263 (87.7) | 22 (73.3) | 1.00 (Reference) | 82 (83.7) | 1.00 (Reference) |
|
| ||||||
| Positive | 37 (12.3) | 8 (26.7) | 1.80 (0.69–4.70) | 16 (16.3) | 1.15 (0.59–2.22) | |
|
| ||||||
| 36 | Negative | 248 (82.7) | 14 (70) | 1.00 (Reference) | 81 (82.7) | 1.00 (Reference) |
|
| ||||||
| Positive | 52 (17.3) | 6 (30) | 1.12 (0.37–3.39) | 17 (17.3) | 0.85 (0.46–1.59) | |
|
| ||||||
| β 2 | ||||||
|
| ||||||
| 9 | Negative | 225 (75) | 6 (66.7) | 1.00 (Reference) | 74 (75.5) | 1.00 (Reference) |
|
| ||||||
| Positive | 75 (25) | 3 (33.3) | 1.02 (0.22–4.63) | 24 (24.5) | 0.93 (0.54–1.60) | |
|
| ||||||
| 15 | Negative | 224 (74.7) | 3 (60) | 1.00 (Reference) | 72 (73.5) | 1.00 (Reference) |
|
| ||||||
| Positive | 76 (25.3) | 2 (40) | 1.48 (0.23–9.48) | 26 (26.5) | 1.00 (0.59–1.71) | |
|
| ||||||
| 17 | Negative | 223 (74.3) | 4 (57.1) | 1.00 (Reference) | 78 (79.6) | 1.00 (Reference) |
|
| ||||||
| Positive | 77 (25.7) | 3 (42.9) | 2.40 (0.49–11.70) | 20 (20.4) | 0.81 (0.46–1.43) | |
|
| ||||||
| 23 | Negative | 239 (79.7) | 1 (20) | 1.00 (Reference) | 81 (82.7) | 1.00 (Reference) |
|
| ||||||
| Positive | 61 (20.3) | 4 (80) | 15.80 (1.60–155.00) | 17 (17.3) | 0.85 (0.46–1.56) | |
|
| ||||||
| 38 | Negative | 226 (75.3) | 21 (75) | 1.00 (Reference) | 78 (79.6) | 1.00 (Reference) |
|
| ||||||
| Positive | 74 (24.7) | 7 (25) | 0.97 (0.37–2.56) | 20 (20.4) | 0.80 (0.45–1.43) | |
|
| ||||||
| β 3 | ||||||
|
| ||||||
| 75 | Negative | 254 (84.7) | 3 (75) | 1.00 (Reference) | 87 (88.8) | 1.00 (Reference) |
|
| ||||||
| Positive | 46 (15.3) | 1 (25) | 2.14 (0.19–24.40) | 11 (11.2) | 0.67 (0.32–1.37) | |
|
| ||||||
| β 4 | ||||||
|
| ||||||
| 92 | Negative | 250 (83.3) | 5 (100) | 1.00 (Reference) | 86 (87.8) | 1.00 (Reference) |
|
| ||||||
| Positive | 50 (16.7) | 0 (0) | 0.00 (NA) | 12 (12.2) | 0.64 (0.32–1.28) | |
|
| ||||||
| β 5 | ||||||
|
| ||||||
| 96 | Negative | 255 (85) | 6 (85.7) | 1.00 (Reference) | 82 (83.7) | 1.00 (Reference) |
|
| ||||||
| Positive | 45 (15) | 1 (14.3) | 0.70 (0.08–6.42) | 16 (16.3) | 0.96 (0.50–1.82) | |
|
| ||||||
| Genus-α2 | ||||||
|
| ||||||
| N | 300 | 7 | 186 | |||
|
| ||||||
| Negative | 194 (64.7) | 3 (42.9) | 1.00 (Reference) | 98 (52.7) | 1.00 (Reference) | |
|
| ||||||
| Positive | 106 (35.3) | 4 (57.1) | 2.53 (0.55–11.72) | 88 (47.3) | 1.64 (1.11–2.44) | |
|
| ||||||
| Genus-γ | ||||||
|
| ||||||
| N | 300 | 17 | 178 | |||
|
| ||||||
| Negative | 145 (48.3) | 6 (35.3) | 1.00 (Reference) | 55 (30.9) | 1.00 (Reference) | |
|
| ||||||
| Positive | 155 (51.7) | 11 (64.7) | 1.40 (0.49–4.00) | 123 (69.1) | 1.97 (1.31–2.97) | |
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; HPV, human papillomavirus; NA, not applicable; OR, odds ratio.
1
ORs and 95% CIs adjusted for age and sex.
2
OR and 95% CI estimations based on a sample size of 193 BCC cases and 300 controls.